Also on Friday, the Food and Drug Administration informally requested that Sarepta voluntarily pause shipments of another gene therapy, Elevidys, which is approved to treat a different type of ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Sarepta Therapeutics slashed its share price by 44 percent last week following price target cuts from two investment companies.

In a market note, Oppenheimer significantly lowered its price target for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to $45 from $123 previously, marking a 63-percent downside.

TD Cowen analyst Ritu Baral maintained a Hold rating on Sarepta Therapeutics today and set a price target of $24.00. The company’s shares closed last Friday at $20.08. According to TipRanks.com, Baral ...

Stay up-to-date on Wall Street's latest analyst calls, stock downgrades, and upgrades for major companies like Sarepta, Cisco, and more.

Sarepta shares face pressure after a second Elevidys-linked death and analyst downgrade over safety concerns and lowered revenue prospects.

On Wednesday, Goldman Sachs reaffirmed its Buy rating and $100.00 price target for Sarepta Therapeutics (NASDAQ: SRPT), following a meeting with Dr. Vinay Prasad, the newly-appointed FDA CBER ...

Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics are included in this Analyst Blog.

On Tuesday, Sarepta Therapeutics (NASDAQ: SRPT), currently trading at $81.07 and near its 52-week low, maintained its Buy rating and $203.00 price target from TD Cowen, despite the reported death of a ...

Nonetheless, the maintained Buy rating and price target by TD Cowen indicate a steady outlook for Sarepta Therapeutics’ stock in the eyes of the analyst firm.